Immunohistochemistry results show that SH003 reduced the expression of Ki-67, phospho-VEGFR2 and vascular endothelial cell marker (CD31), and increased apoptosis marker (cleaved caspase 3) in tumor tissues, suggesting that SH003 administration decreased the tumor growth by inhibiting tumor angiogenesis. Here, CASP3 is linked to neoplasm.